Comparison · NCT02314247-sae
Selinexor (PTCL) vs Selinexor (CTCL): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Selinexor (PTCL) vs Selinexor (CTCL): serious adverse events. Trial comparisons, record NCT02314247-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02314247-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.889 | 0.565 | 0.98 | wilson | |
| Risk in group 2 | 0.143 | 0.0257 | 0.513 | wilson | |
| Risk difference, group 1 minus group 2 | 0.746 | 0.254 | 0.895 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 6.22 | 0.999 | 38.8 | log | |
| Odds ratio, group 1 over group 2 | 48 | 2.47 | 933 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Selinexor (PTCL) than on Selinexor (CTCL) | 1.34 | 1.12 | 3.94 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Selinexor (PTCL) | Assigned to 60 mg; 6 doses/cycle | 8 | 9 | EG000 |
| Group 2 | Selinexor (CTCL) | Assigned to 60 mg; 6 doses/cycle (6 patients)~Assigned to 60 mg; 8 doses/cycle (1 patient) | 1 | 7 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Day of onset after the first dose of study treatment through 30 days following the last dose of study treatment.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
- NCT number
- NCT02314247
- Phases
- PHASE2
- Conditions
- Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
- Interventions
- Selinexor
- Lead sponsor
- Karyopharm Therapeutics Inc
- Results first posted
- 2018-08-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02314247?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02314247-sae